These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19694582)

  • 1. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
    Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
    Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
    Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
    J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
    Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
    QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
    Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
    Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of High-Specific-Activity
    Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
    J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I clinical trial for [
    Inaki A; Yoshimura K; Murayama T; Imai Y; Kuribayashi Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
    J Med Invest; 2017; 64(3.4):205-209. PubMed ID: 28954983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
    Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
    Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ
    J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
    Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
    Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic effectiveness of 131I-MIBG on malignant pheochromocytoma--results of long-term follow-up].
    Kusakabe K; Kanaya K; Kanaya S; Yazaki E; Nakano K; Matsumoto N; Kobayashi H; Maki M; Itou Y; Obara T
    Kaku Igaku; 1994 Dec; 31(12):1495-502. PubMed ID: 7861648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
    Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
    Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
    Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA
    Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
    Brans B; Monsieurs M; Laureys G; Kaufman JM; Thierens H; Dierckx RA
    Med Pediatr Oncol; 2002 Jan; 38(1):41-6. PubMed ID: 11835235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
    Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
    Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
    Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.